"The key elements of the Act: [1] impose on certain health plans targeted consumer cost-sharing limitations for selected pharmaceuticals used to treat delineated chronic conditions; [2] impose mandatory licensing and regulation of PBMs, including constraints on to-be-defined PBM conflicts of interest; and [3] require PBMs and pharmaceutical manufacturers to comply with detailed cost and pricing data reporting requirements[.]"  MORE >>